Telisotuzumab vedotin (ABBV-399) is a MET-targeting ADC that showed antitumor activity in c-Met-positive NSCLC patients with a favorable safety profile in two phase I studies [222, 223]. This evidence concerns the gene MET and non-small cell lung carcinoma.